florbetapir-f-18 and Cerebral-Small-Vessel-Diseases

florbetapir-f-18 has been researched along with Cerebral-Small-Vessel-Diseases* in 1 studies

Other Studies

1 other study(ies) available for florbetapir-f-18 and Cerebral-Small-Vessel-Diseases

Article	Year
Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. Annals of neurology, 2021, Volume: 89, Issue:2 African Americans are at greater risk for developing Alzheimer's disease (AD) dementia than non-Hispanic whites. In addition to biological considerations (eg, genetic influences and comorbid disorders), social and environmental factors may increase the risk of AD dementia. This paper (1) assesses neuroimaging biomarkers of amyloid (A), tau (T), and neurodegeneration (N) for potential racial differences and (2) considers mediating effects of socioeconomic status (SES) and measures of small vessel and cardiovascular disease on observed race differences.. Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic resonance imaging (MRI), and resting state functional connectivity (rs-fc) were collected from African American (n = 131) and white (n = 685) cognitively normal participants age 45 years and older. Measures of small vessel and cardiovascular disease (white matter hyperintensities [WMHs] on MRI, blood pressure, and body mass index [BMI]) and area-based SES were included in mediation analyses.. Compared to white participants, African American participants had greater neurodegeneration, as measured by decreased cortical volumes (Cohen's f. Modifiable factors, such as differences in social contexts and resources, particularly area-level SES, may contribute to observed racial differences in AD. Future studies should emphasize collection of relevant psychosocial factors in addition to the development of intentional diversity and inclusion efforts to improve the racial/ethnic and socioeconomic representativeness of AD studies. ANN NEUROL 2021;89:254-265. Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Black or African American; Brain; Carbolines; Cerebral Small Vessel Diseases; Ethylene Glycols; Female; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Mediation Analysis; Middle Aged; Neuroimaging; Positron-Emission Tomography; Radiopharmaceuticals; Social Class; tau Proteins; Thiazoles; White	2021

Article

Year

Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.

Annals of neurology, 2021, Volume: 89, Issue:2

African Americans are at greater risk for developing Alzheimer's disease (AD) dementia than non-Hispanic whites. In addition to biological considerations (eg, genetic influences and comorbid disorders), social and environmental factors may increase the risk of AD dementia. This paper (1) assesses neuroimaging biomarkers of amyloid (A), tau (T), and neurodegeneration (N) for potential racial differences and (2) considers mediating effects of socioeconomic status (SES) and measures of small vessel and cardiovascular disease on observed race differences.. Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic resonance imaging (MRI), and resting state functional connectivity (rs-fc) were collected from African American (n = 131) and white (n = 685) cognitively normal participants age 45 years and older. Measures of small vessel and cardiovascular disease (white matter hyperintensities [WMHs] on MRI, blood pressure, and body mass index [BMI]) and area-based SES were included in mediation analyses.. Compared to white participants, African American participants had greater neurodegeneration, as measured by decreased cortical volumes (Cohen's f. Modifiable factors, such as differences in social contexts and resources, particularly area-level SES, may contribute to observed racial differences in AD. Future studies should emphasize collection of relevant psychosocial factors in addition to the development of intentional diversity and inclusion efforts to improve the racial/ethnic and socioeconomic representativeness of AD studies. ANN NEUROL 2021;89:254-265.

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Black or African American; Brain; Carbolines; Cerebral Small Vessel Diseases; Ethylene Glycols; Female; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Mediation Analysis; Middle Aged; Neuroimaging; Positron-Emission Tomography; Radiopharmaceuticals; Social Class; tau Proteins; Thiazoles; White

2021